Nemaura Medical Inc.
NMRD · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$1,553 |
| % Growth | – | – | 100% | – |
| Cost of Goods Sold | $80 | $0 | $0 | $3,032 |
| Gross Profit | -$80 | $0 | $0 | -$4,585 |
| % Margin | – | – | – | 295.2% |
| R&D Expenses | $291 | $492 | $550 | $558 |
| G&A Expenses | $1,250 | $1,559 | $1,508 | $1,271 |
| SG&A Expenses | $1,250 | $1,559 | $1,508 | $1,271 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $980 |
| Operating Expenses | $1,541 | $2,051 | $2,058 | $1,829 |
| Operating Income | -$1,541 | -$2,051 | -$1,834 | -$4,287 |
| % Margin | – | – | – | 276% |
| Other Income/Exp. Net | -$620 | $847 | -$769 | -$396 |
| Pre-Tax Income | -$2,161 | -$1,203 | -$2,603 | -$4,683 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,161 | -$1,203 | -$2,603 | -$328 |
| % Margin | – | – | – | 21.1% |
| EPS | -0.075 | -0.042 | -0.09 | -0.013 |
| % Growth | -79.8% | 53.8% | -582.6% | – |
| EPS Diluted | -0.075 | -0.042 | -0.09 | -0.013 |
| Weighted Avg Shares Out | 28,899 | 28,899 | 28,899 | 24,878 |
| Weighted Avg Shares Out Dil | 28,899 | 28,899 | 28,899 | 24,878 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,926 | $825 | $657 | $2,260 |
| Depreciation & Amortization | $80 | $131 | $98 | $176 |
| EBITDA | -$155 | -$247 | -$1,848 | -$2,247 |
| % Margin | – | – | – | 144.7% |